Olyrian Diagnostics Name Announced for Planned Standalone Business

Siemens Healthineers said it has initiated the carve-out process for its in vitro diagnostics business, a step toward a planned standalone company to be called Olyrian Diagnostics. The transition is expected to be completed by mid-2028, and the name will be rolled out in stages. Siemens Healthineers also said it will change its own name to Healthineers, with both transitions running in parallel. Siemens Healthineers Press Releases report.

A Carve-Out With Its Own Identity, Not a Parent Rebranding

Siemens Healthineers said establishing Olyrian is the next step in preparing Diagnostics to operate as a standalone organization. The company describes a dedicated name and brand as a way to give the business a distinct market presence, focused on laboratory and point-of-care diagnostics.

Separately, Siemens Healthineers said it will change its name to Healthineers. The announcement states that the two transitions will take place in parallel. Our recommendation is not to infer a completed sale or listing from the branding announcement.

Planned, Not Completed: What Changes Now and What Does Not

The carve-out has been initiated; the standalone organization has not been completed. Olyrian remains part of Siemens Healthineers during the transition. As of the announcement, the company said there is no change to products and services, contracts, service levels or customer points of contact, and that customers can expect the same commitment to quality, service and innovation throughout the transition.

The company said updates will be provided as the carve-out evolves and that any future changes will be communicated directly. It expects the transition to a standalone organisation to be completed by mid-2028.

The Stated Purpose and Scope of Olyrian

Olyrian's stated purpose is powering human potential at the heart of care. The company says the business will advance diagnostics along the care continuum, from patient draw to population health, delivering diagnostic solutions for laboratory and point-of-care testing. It also describes a focus on combining intelligent technology with the expertise of people who make, interpret and act on diagnostic information.

These are vendor-stated objectives, not guarantees of clinical or commercial outcomes. Buyers should evaluate the stated ambitions separately from evidence about individual diagnostic products. The scope described is in vitro diagnostics, with laboratory automation, informatics and point-of-care testing included in the current portfolio.

A Century-Old Testing Legacy Behind the New Name

Siemens Healthineers said its in vitro diagnostics business has a legacy in diagnostic testing extending more than a century. The company said it established the business after acquiring three companies in 2006 and 2007, whose histories date back to as early as 1884.

The company said the business manufactures more than 16 billion tests annually across an assay portfolio addressing nearly every major disease area. It cites the first urine test strip for diabetes and what it describes as the industry's first automated, integrated clinical chemistry and immunoassay analyzer among its innovations. As Olyrian, the business says it will build on that legacy.

What This Means for Practitioners

For laboratory and point-of-care teams, the practical message is continuity during the transition. The company says contracts, service levels and customer contacts are unchanged as of the announcement, so operational planning does not need to assume an immediate shift in suppliers or workflows based on this release alone.

The branding change is staged, meaning practitioners may encounter the Olyrian name progressively rather than at once. The company says future changes will be communicated directly. Our recommendation is to monitor that communication for the rollout details and progress toward the planned mid-2028 completion, rather than treating the intended standalone structure as already established.